[Market Focus] Rokit Healthcare Rises on News of Skin Regeneration Clinical Case Announcement

As of 9:30 a.m. on July 3, shares of Rokit Healthcare on the KOSDAQ market were trading at 17,240 won, up 14.63% from the previous day's closing price. This appears to be due to news of the announcement of a clinical case of skin regeneration in skin cancer patients.

Rokit Healthcare, a company specializing in patient-specific organ regeneration platforms, announced on July 3 that it had presented a case at the 17th Annual Meeting of the Japanese Society for Wound Healing in Tokyo, in which normal skin tissue was completely reconstructed within four weeks using only AI regenerative therapy for an elderly skin cancer patient who was previously ineligible for conventional surgery or transplantation. The clinical trial was conducted and presented by Professor Hajime Matsumura, President of the Japanese Society for Wound Healing and faculty member at Tokyo Medical University, and was also published in the SCI international journal, Journal of Clinical Medicine.

Rokit Healthcare possesses a platform technology that, rather than simple skin grafting, uses AI analysis to precisely diagnose the tissue structure of lesions and to design, print, and transplant patient-specific regenerative tissue. As a result, the company achieved complete skin regeneration in an average of 4.2 weeks, and an excellent patient satisfaction score, with an average of 280 out of 300 points on the SCAR-Q aesthetic assessment. Clinical results showed that patients experienced no immune rejection and minimal scarring. In particular, the technology demonstrated superiority over conventional surgery in cosmetically important areas such as the nose, forehead, and cheeks. Its applicability to patients who are elderly or have systemic diseases and are therefore ineligible for conventional treatments is a significant advantage.

Skin cancer is a representative type of cancer that is rapidly increasing due to factors such as population aging and climate change, including global warming. Among these, non-melanoma skin cancer is a high-frequency disease with millions of surgeries performed annually. According to market research firm IMARC, as of last year, the skin cancer regeneration market was valued at approximately $400 million to $700 million and is expected to grow to over $900 million by 2030.

A Rokit Healthcare representative stated, "Based on these results, we plan to begin full-scale commercialization of the AI skin regeneration platform in major global regions such as Japan, Korea, the United States, Europe, and South America in the second half of this year." The representative added, "Building on the AI skin regeneration technology proven in diabetic foot treatment, we are expanding the application of the platform to a variety of fields, including pressure ulcers, traumatic skin defects, severe burns, and high-risk wounds."